Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emma Cacciola

Showing results (31-40 of 37) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 37 results.
Leukemia Research|July 19, 2011
Low impact of cardiovascular adverse events on anagrelide treatment discontinuation in a cohort of 232 patients with essential thrombocythemiaLuigi Gugliotta, Alessia Tieghi, Giovanni Tortorella, et al.
American Journal of Hematology|April 5, 2012
Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPNElisabetta Antonioli, Paola Guglielmelli, Lisa Pieri, et al.
American Journal of Hematology|July 22, 2014
Cerebral vein thrombosis in patients with Philadelphia-negative myeloproliferative neoplasms. An European Leukemia Net studyIda Martinelli, Valerio De Stefano, Alessandra Carobbio, et al.
The Lancet. Haematology|January 21, 2021
Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trialTiziano Barbui, Alessandro Maria Vannucchi, Valerio De Stefano, et al.
NEJM Evidence|February 6, 2024
Ropeginterferon versus Standard Therapy for Low-Risk Patients with Polycythemia VeraTiziano Barbui, Alessandro Maria Vannucchi, Valerio De Stefano, et al.
Annals of Hematology|December 7, 2023
Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomesTiziano Barbui, Alessandra Carobbio, Valerio De Stefano, et al.
Blood Cancer Journal|March 15, 2018
Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasmsValerio De Stefano, Alessandra Carobbio, Vincenzo Di Lazzaro, et al.
Pageof 4

Showing results (31-40 of 37) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 37 results.
Leukemia Research|July 19, 2011
Low impact of cardiovascular adverse events on anagrelide treatment discontinuation in a cohort of 232 patients with essential thrombocythemiaLuigi Gugliotta, Alessia Tieghi, Giovanni Tortorella, et al.
American Journal of Hematology|April 5, 2012
Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPNElisabetta Antonioli, Paola Guglielmelli, Lisa Pieri, et al.
American Journal of Hematology|July 22, 2014
Cerebral vein thrombosis in patients with Philadelphia-negative myeloproliferative neoplasms. An European Leukemia Net studyIda Martinelli, Valerio De Stefano, Alessandra Carobbio, et al.
The Lancet. Haematology|January 21, 2021
Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trialTiziano Barbui, Alessandro Maria Vannucchi, Valerio De Stefano, et al.
NEJM Evidence|February 6, 2024
Ropeginterferon versus Standard Therapy for Low-Risk Patients with Polycythemia VeraTiziano Barbui, Alessandro Maria Vannucchi, Valerio De Stefano, et al.
Annals of Hematology|December 7, 2023
Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomesTiziano Barbui, Alessandra Carobbio, Valerio De Stefano, et al.
Blood Cancer Journal|March 15, 2018
Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasmsValerio De Stefano, Alessandra Carobbio, Vincenzo Di Lazzaro, et al.
Pageof 4